Using End-Tidal CO₂ to Help Diagnose and Monitor Pulmonary Embolism
A legfontosabb adatok
- Ki végzi
- Ataturk University
- Hol
- Törökország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 120 fő vett részt
- Kezdés
- 2025. febr. 1.
- Befejezés
- 2025. júl. 30.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A vizsgált kezelések
- thrombolytic therapy
- A regiszteradat frissítve
- 2025. december 22.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
A regiszter feltételei, szó szerint
Mind a 2 feltétel megnézéseKevesebb
Ki vehet részt
- Adults aged 18 years or older Diagnosis of acute pulmonary embolism confirmed by CT pulmonary angiography (for PE groups) Classified as high-risk or intermediate-high-risk pulmonary embolism according to ESC/ERS 2019 guidelines Ability to provide informed consent For healthy control group: no history of cardiopulmonary disease, coagulation disorders, or acute medical illness
Ki nem vehet részt
- Known chronic respiratory diseases significantly affecting EtCO₂ measurement (e.g., advanced COPD, severe asthma, chronic respiratory failure) Active infection, sepsis, or acute complications of malignancy Prior thrombolytic therapy for pulmonary embolism Anatomical or technical limitations preventing reliable nasal capnography Pregnancy Individuals younger than 18 years Inability or refusal to provide informed consent
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Pulmonary embolism (PE) can reduce blood flow in the lungs and impair gas exchange, leading to lower end-tidal carbon dioxide (EtCO₂) levels. This prospective observational study aims to evaluate whether EtCO₂ can help identify high-risk and intermediate-high-risk patients and monitor early treatment response, especially during thrombolytic therapy. A total of 120 participants were included: high-risk PE, intermediate-high-risk PE patients who received thrombolysis, intermediate-high-risk PE patients treated only with anticoagulation, and healthy controls.
A teljes eredeti leírásKevesebb
The study measured EtCO₂ along with oxygen saturation, heart rate, respiratory rate, perfusion index, and radiological obstruction scores. By comparing these parameters at diagnosis and during the first 24 hours, the study seeks to determine whether EtCO₂ can serve as a simple, noninvasive marker of disease severity and early hemodynamic improvement in patients with acute PE.
A vizsgálat 4 csoportja
- Group 1: High-Risk Pulmonary Embolism (Thrombolysis)
Patients presenting with shock or persistent hypotension and receiving systemic thrombolytic therapy.
Kezelés: thrombolytic therapy
- Group 2: Intermediate-High-Risk Pulmonary Embolism (Thrombolysis)
Hemodynamically stable patients with RV dysfunction and elevated biomarkers who required thrombolysis.
Kezelés: thrombolytic therapy
- Group 3: Intermediate-High-Risk Pulmonary Embolism (Non-Thrombolysis)
Patients meeting intermediate-high-risk criteria but treated with anticoagulation only.
- Group 4: Healthy Controls
Individuals without cardiopulmonary disease and with normal clinical and laboratory findings.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Assessment of End-Tidal CO₂ Levels in the Diagnosis and Management of Patients With Pulmonary Embolism
- Publikációk
- Assessment of end-tidal CO₂ levels in the diagnosis and management of patients with pulmonary embolism.BMC pulmonary medicine, 2026
- A regiszteradat frissítve
- 2025. december 22.